Physician profile
Ralph R Madeb
NPI 1073627337
$15,706.07
in general payments reported to CMS, 2019-2025
10 companies · $565 in 2025
The $565 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2022: $82.65 · 2023: $15K · 2024: $17.72 · 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $15K · Food and Beverage: $524 · Travel and Lodging: $58.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $14,906.43 |
| Food and Beverage | $523.99 |
| Travel and Lodging | $58.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $14,888.13 | 2023 | Oes Cystonephrofiberscope, Olympus |
| Edap Technomed INC | $273.75 | 2025 | |
| Amgen INC. | $250.00 | 2025 | Tepezza |
| Astellas Pharma US INC | $170.65 | 2019-2022 | |
| C. R. Bard, INC. & Subsidiaries | $31.90 | 2019 | |
| Coloplast Corp | $22.48 | 2025 | |
| Baxter Healthcare | $18.30 | 2025 | |
| Boston Scientific Corporation | $18.17 | 2023 | Lumenis Pulse 120h |
| Novo Nordisk INC | $17.72 | 2024 | Rybelsus |
| Pfizer INC. | $14.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Madeb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.